The Dissociated Expression of Protein and Messenger RNA of DPC4 in Human Invasive Ductal Carcinoma of the Pancreas and their Implication for Patient Outcome

Anticancer Research

Volumn 24, Issue 2 C, 2004, Pages 1173-1178

  Toga, Tomoko ^a   Nio, Yoshinori ^a   Hashimoto, Koji ^a   Higami, Tetsuya ^a   Maruyama, Riruke ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

Adjuvant chemotherapy; DPC4; Pancreatic cancer; SMAD 4

Indexed keywords

CYCLOPHOSPHAMIDE; GEMCITABINE; GENE PRODUCT; MESSENGER RNA; SMAD4 PROTEIN; UFT;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE STUDY; CORRELATION COEFFICIENT; DIAGNOSTIC VALUE; DPC4 GENE; FEMALE; GENE FUNCTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; ONCOGENE; PANCREAS CARCINOMA; PANCREAS INVASIVE DUCTAL CARCINOMA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL RATE;

AGED; CARCINOMA, PANCREATIC DUCTAL; CHEMOTHERAPY, ADJUVANT; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; RNA, MESSENGER; SMAD4 PROTEIN; TRANS-ACTIVATORS; TREATMENT OUTCOME;

EID: 2442533068     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Hahn SA, Hoque AT, Moskaluk CA et al: Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res 56: 490-494, 1996.
2. Hahn SA, Schutte M, Hoque AT et al: DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271: 350-353, 1996.
3. Wilentz RE, Iacobuzio-Donahue CA, Argani P et al: Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 60: 2002-2006, 2000.
4. Tascilar M, Skinner HG, Rosty C et al: The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res 7: 4115-4121, 2001.
5. Wilentz RE, Su GH, Dai JL et al: Immunohistochemical labeling for Dpc4 mirrors genetic status in pancreatic adenocarcinomas: a new marker of DPC4 inactivation. Am J Pathol 156: 37-43, 2000.
6. Iacobuzio-Donahue CA, Klimstra DS, Adsay NV et al: Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas. Am J Pathol 157: 755-761, 2000.
7. Liu F: SMAD4/DPC4 and pancreatic cancer survival. Commentary re: M. Tascilar et al.: The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res 7: 4115-4121, 2001. Clin Cancer Res 7: 3853-3856, 2001.
8. Liu F: SMAD4/DPC4 and pancreatic cancer survival. Commentary re: M. Tascilar et al.: The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res 7: 4115-4121, 2001. Clin Cancer Res 7: 3853-3856, 2001.
9. Sohn TA, Yeo CJ, Cameron JL et al: Intraductal papillary mucinous neoplasms of the pancreas: an increasingly recognized clinicopathologic entity. Ann Surg 234: 313-321; discussion 321-322, 2001.
10. Komminoth P: Digoxigenin as an alternative probe labeling for in situ hybridization. Diagn Mol Pathol 1: 142-150, 1992.
11. Thomas GA, Davies HG and Williams ED: Demonstration of mRNA using digoxigenin labelled oligonucleotide probes for in situ hybridisation in formamide free conditions. J Clin Pathol 46: 171-174, 1993.
12. Schutte M: DPC4/SMAD4 gene alterations in human cancer, and their functional implications. Ann Oncol 10(Suppl 4): S56-S59, 1999.
13. Kiyama H and Emson PC: An in situ hybridization histochemistry method for the use of alkaline phosphatase-labeled oligonucleotide probes in small intestine. J Histochem Cytochem 39: 1377-1384, 1991.
14. Mokry J: Versatility of immunohistochemical reactions: comprehensive survey of detection systems. Acta Medica (Hradec Králové) 39: 129-140, 1996.
15. Sabattini E, Bisgaard K, Ascani S et al: The EnVisionTM+ system: a new immunohistochemical method for diagnostics and research. Critical comparison with the APAAP, ChemMateTM, CSA, LABC, and SABC techniques. J Clin Pathol 51: 506-511, 1998.
16. Dai JL, Bansal RK and Kern SE: G1 cell cycle arrest and apoptosis induction by nuclear Smad4/Dpc4: Phenotypes reversed by a tumorigenic mutation. Proc Natl Acad Sci USA 96: 1427-1432, 1999.
17. Cooper KM, Kennedy S, McConnell S et al: An immunohistochemical study of the distribution of biotin in tissues of pigs and chickens. Res Vet Sci 63: 219-225, 1997.
18. Barberá VM, Martín M, Marinõso L et al: The 18q21 region in colorectal and pancreatic cancer: independent loss of DCC and DPC4 expression. Biochim Biophys Acta 1502: 283-296, 2000.
19. Fukuchi M, Masuda N, Miyazaki T et al: Decreased Smad4 expression in the transforming growth factor-beta signaling pathway during progression of esophageal squamous cell carcinoma. Cancer 95: 737-743, 2002.
20. Shi Y, Hata A, Lo RS et al: A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature 388(6637): 87-93, 1997.
21. Maurice D, Pierreux CE, Howell M et al: Loss of Smad4 function in pancreatic tumors: C-terminal truncation leads to decreased stability. J Biol Chem 276: 43175-43181, 2001.
22. Xu J and Attisano L: Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 97: 4820-4825, 2000.